Net profit of Vimta Labs rose 140.92% to Rs 15.25 crore in the quarter ended September 2024 as against Rs 6.33 crore during the previous quarter ended September 2023. Sales rose 29.30% to Rs 84.74 crore in the quarter ended September 2024 as against Rs 65.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales84.7465.54 29 OPM %35.3026.56 - PBDT30.1818.84 60 PBT21.8910.19 115 NP15.256.33 141 Powered by Capital Market - Live News

Vimta Labs will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live News

Vimta Labs has completed the sale and transfer of its diagnostic and pathological services business as a going concern to Thyrocare Technologies on 11 October 2024. Powered by Capital Market - Live News

Net profit of Vimta Labs rose 0.66% to Rs 12.28 crore in the quarter ended June 2024 as against Rs 12.20 crore during the previous quarter ended June 2023. Sales declined 2.07% to Rs 81.76 crore in the quarter ended June 2024 as against Rs 83.49 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales81.7683.49 -2 OPM %29.9929.52 - PBDT24.7424.80 0 PBT16.5216.30 1 NP12.2812.20 1 Powered by Capital Market - Live News

Vimta Labs will hold a meeting of the Board of Directors of the Company on 17 July 2024.Powered by Capital Market - Live News